Cost-Effectiveness Analysis of Screening for KRAS and BRAF Mutations in Metastatic Colorectal Cancer

Defining the Optimal Therapy Sequence in Synchronous Resectable Liver Metastases from Colorectal Cancer: A Decision Analysis Approach

(2016) E. Van Dessel et al.   ACTA CHIRURGICA BELGICA

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

(2011) C. Bokemeyer et al.   ANNALS OF ONCOLOGY

KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective

(2011) P. R. Blank et al.   CLINICAL CANCER RESEARCH

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost-Effectiveness of HIV Screening in STD Clinics, Emergency Departments, and Inpatient Units: A Model-Based Analysis

(2011) Vimalanand S. Prabhu et al.   PLoS One

Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases

(2010) L J M Mekenkamp et al.   BRITISH JOURNAL OF CANCER

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab

(2010) Jolien Tol et al.   EUROPEAN JOURNAL OF CANCER

Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer

(2010) Thomas Winder et al.   GASTROENTEROLOGY

Colorectal cancer

(2010) David Cunningham et al.   LANCET

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors

(2009) E. E. Mancl et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment

(2009) Emmanuel Mitry et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy

(2009) Scott Kopetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial

(2009) N. Mittmann et al.   JNCI-Journal of the National Cancer Institute

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

(2009) Gunnar Folprecht et al.   LANCET ONCOLOGY

At what costs will screening with CT colonography be competitive? A cost-effectiveness approach

(2008) Iris Lansdorp-Vogelaar et al.   INTERNATIONAL JOURNAL OF CANCER

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

(2008) Carsten Bokemeyer et al.   JOURNAL OF CLINICAL ONCOLOGY

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE